Canaccord analyst Sumant Kulkarni raised the firm’s price target on Acadia Pharmaceuticals to $24 from $20 and keeps a Buy rating on the shares. The analyst said they issued a 2023 sales outlook for Nuplazid of $520-550mn. We view this as solid especially when viewed against some headwinds the product has faced in terms of in-office channel visits remaining below pre-pandemic levels.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ACAD:
- This ETF Has 67% Upside Potential, According to Analysts
- Acadia Pharmaceuticals price target raised to $27 from $19 at RBC Capital
- Acadia Pharmaceuticals price target raised to $19 from $15 at Mizuho
- Acadia Pharmaceuticals sees FY23 revenue $520M-$550M, consensus $569.2M
- Acadia Pharmaceuticals reports Q4 EPS (26c), consensus (24c)
